^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    brigimadlin (BI 907828)

    i
    Other names: BI 907828, BI-907828
    Company:
    Boehringer Ingelheim
    Drug class:
    MDM2-p53 antagonist
    2d
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=119, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    29d
    Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P3, N=263, Not yet recruiting, Boehringer Ingelheim
    New P3 trial • Combination therapy • Metastases
    |
    gemcitabine • docetaxel • brigimadlin (BI 907828) • ezabenlimab (BI 754091)
    1m
    Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P3, N=240, Recruiting, Boehringer Ingelheim | Initiation date: Mar 2023 --> Dec 2023
    Trial initiation date • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    brigimadlin (BI 907828)
    2ms
    Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P3, N=240, Recruiting, Boehringer Ingelheim | Initiation date: Dec 2023 --> Mar 2023
    Trial initiation date • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    brigimadlin (BI 907828)
    2ms
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=140, Recruiting, Boehringer Ingelheim | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    4ms
    Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. (PubMed, Future Oncol)
    Brigimadlin (BI 907828) is a highly potent MDM2-p53 antagonist that has shown promising activity in preclinical and early-phase clinical studies. This manuscript describes the rationale and design of an ongoing phase IIa/IIb Brightline-2 trial evaluating brigimadlin as second-line treatment for patients with advanced/metastatic BTC, PDAC, lung adenocarcinoma, or bladder cancer.
    P2a data • Review • Journal • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification + TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828)
    5ms
    Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P3, N=240, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    brigimadlin (BI 907828)
    6ms
    Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (clinicaltrials.gov)
    P2, N=155, Recruiting, Boehringer Ingelheim | Phase classification: P2a/2b --> P2
    Phase classification
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    6ms
    This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=269, Recruiting, Boehringer Ingelheim | Phase classification: P1a/1b --> P1 | N=204 --> 269
    Phase classification • Enrollment change • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    6ms
    A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body (clinicaltrials.gov)
    P1, N=16, Recruiting, Boehringer Ingelheim | Trial primary completion date: Feb 2024 --> May 2024
    Trial primary completion date • Metastases
    |
    brigimadlin (BI 907828)
    7ms
    Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics (GlobeNewswire)
    "Burning Rock Biotech Limited...is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese patients with safer, more efficient, and precise treatment options and diagnostic methods, thereby promoting innovation and development in cancer treatment. This partnership will primarily focus on advancing the clinical trials related to Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin (BI 907828), and the development of companion diagnostic products in China."
    Licensing / partnership
    |
    brigimadlin (BI 907828)
    7ms
    EMPIRE: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Institut Bergonié
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091)
    7ms
    Delivery versus potency in treating brain tumors: BI-907828, a MDM2-p53 antagonist with limited BBB penetration but significant in vivo efficacy in glioblastoma. (PubMed, Mol Cancer Ther)
    These studies show that efficacy of BI-907828 in orthotopic models is related to high potency even though its CNS distribution is limited by BBB efflux. Therefore, a comprehensive understanding of all aspects of the "Delivery - Potency - Efficacy" relationship is warranted in drug discovery and development, especially for treatment of CNS tumors.
    Preclinical • Journal
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828)
    8ms
    Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P3, N=240, Not yet recruiting, Boehringer Ingelheim
    New P3 trial • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    brigimadlin (BI 907828)
    8ms
    Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P2/3, N=386, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    doxorubicin hydrochloride • brigimadlin (BI 907828)
    9ms
    A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor (clinicaltrials.gov)
    P1, N=32, Recruiting, Boehringer Ingelheim | N=16 --> 32 | Trial primary completion date: Aug 2023 --> Aug 2024
    Enrollment change • Trial primary completion date • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • itraconazole • rifampicin
    9ms
    LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST (CTOS 2023)
    This mutation analysis represents one of the most robust assessments of longitudinal ctDNA by NGS for TP53 from an MDM2–p53 antagonist trial in liposarcoma. While acquired mutations in TP53 are very common, these data suggest that brigimadlin does not systematically lead to broad acquisition of resistance by inducing alterations in TP53.
    Clinical • P1 data • Circulating tumor DNA
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type • TP53 R175H • TP53 R248Q • TP53 R273H
    |
    brigimadlin (BI 907828)
    9ms
    The MDM2-p53 antagonist BI 907828 in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study. (PubMed, Cancer Discov)
    As evidence of target engagement, time- and dose-dependent increases in GDF-15 levels were seen. Preliminary efficacy was encouraging (11.1% overall response and 74.1% disease control rates), particularly in well-differentiated or dedifferentiated liposarcoma patients (100% and 75% disease control rates, respectively).
    P1 data • Journal • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase) • GDF15 (Growth differentiation factor 15)
    |
    brigimadlin (BI 907828)
    10ms
    MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation. (PubMed, Biomedicines)
    While some MDM2 inhibitors have progressed to early phase clinical trials in GBM, their efficacy, alone and in combination, is yet to be confirmed. In this article, we present an overview of MDM2 inhibitors currently under preclinical and clinical investigation, with a specific focus on the drugs being assessed in ongoing clinical trials for GBM patients.
    Review • Journal
    |
    TP53 wild-type
    |
    navtemadlin (KRT-232) • idasanutlin (RG7388) • brigimadlin (BI 907828) • ALRN-6924
    10ms
    A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours (ESMO 2023)
    Conclusions BI 907828 demonstrated antitumour activity and a manageable safety profile in pts with advanced solid tumours, including those with BTC; dose expansion is ongoing. BI 907828 is being further assessed in pts with BTC in the phase IIa/IIb open-label Brightline-2 trial (NCT05512377).
    Clinical • P1 data
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification + TP53 wild-type
    |
    brigimadlin (BI 907828)
    11ms
    New targeted treatments for advanced sarcomas. (PubMed, Curr Opin Oncol)
    Molecular-guided precision medicine holds a bright future in bringing more active treatments for advanced sarcoma patients.
    Journal • IO biomarker • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase) • XPO1 (Exportin 1) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    CDK4 amplification • MDM2 overexpression • MDM2 amplification + CDK4 amplification • SS18-SSX fusion
    |
    imatinib • Xpovio (selinexor) • Tazverik (tazemetostat) • milademetan (RAIN-32) • Fyarro (nanoparticle albumin-bound rapamycin) • brigimadlin (BI 907828)
    1year
    Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. (PubMed, Future Oncol)
    BI 907828 has shown promising activity in preclinical studies and in a phase Ia/Ib study in patients with solid tumors, particularly those with DDLPS. This manuscript describes the rationale and design of an ongoing multicenter, randomized, phase II/III trial (Brightline-1; NCT05218499) evaluating BI 907828 versus doxorubicin as first-line treatment for advanced DDLPS.
    P2/3 data • Review • Journal • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    doxorubicin hydrochloride • brigimadlin (BI 907828)
    1year
    Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours (ESMO-GI 2023)
    Currently, ten patients with BTC had received BI 907828 ± ezabenlimab (an immune checkpoint inhibitor). The final primary analysis will be performed after all treated patients have been followed for ≥12 weeks, or until study discontinuation. As of February 2023, 16 patients have been enrolled.Clinical trial identification: NCT05512377.Editorial acknowledgement: Medical writing assistance, funded by Boehringer Ingelheim, was provided by Jim Sinclair, PhD, of Ashfield MedComms, an Inizio Company, during the preparation of this abstract.Legal entity responsible for the study: Boehringer Ingelheim.
    Clinical • P2a data • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • MDM2 amplification + TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091)
    1year
    Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (clinicaltrials.gov)
    P2a/2b, N=155, Recruiting, Boehringer Ingelheim | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    1year
    Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist. (ASCO 2023)
    This mutation analysis represents one of the most comprehensive assessments of longitudinal ctDNA by NGS for TP53 from a clinical trial of an MDM2–p53 antagonist. Preliminary data suggest that BI 907828 does not systematically lead to broad acquisition of resistance by inducing alterations in TP53. Clinical trial information: NCT03449381.
    Clinical • P1 data • Circulating tumor DNA
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type • TP53 R175H • TP53 R248Q
    |
    brigimadlin (BI 907828)
    1year
    A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor (clinicaltrials.gov)
    P1, N=16, Recruiting, Boehringer Ingelheim | Trial completion date: Jun 2024 --> Jun 2025
    Trial completion date • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • itraconazole • rifampicin
    1year
    Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P2/3, N=390, Recruiting, Boehringer Ingelheim | N=300 --> 390
    Enrollment change • Metastases
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    doxorubicin hydrochloride • brigimadlin (BI 907828)
    over1year
    Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care (Foundation Medicine Press Release)
    "Foundation Medicine, Inc...announced a global collaboration with Boehringer Ingelheim to develop the company’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for Boehringer Ingelheim’s investigational MDM2-p53 antagonist, BI 907828, in the United States, Japan and European Union."
    Licensing / partnership
    |
    FoundationOne® CDx
    |
    brigimadlin (BI 907828)
    over1year
    Brightline-2: A Study to Test Whether BI 907828 Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (clinicaltrials.gov)
    P2a/2b, N=130, Recruiting, Boehringer Ingelheim | N=100 --> 130
    Enrollment change • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    over1year
    BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. (PubMed, Neuro Oncol)
    BI-907828 provides a promising new therapeutic option for patients with TP53 wild-type primary brain tumors.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • GDF15 (Growth differentiation factor 15) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    TP53 mutation • TP53 wild-type
    |
    temozolomide • brigimadlin (BI 907828)
    over1year
    Brightline-2: A Study to Test Whether BI 907828 Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (clinicaltrials.gov)
    P2a/2b, N=100, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    over1year
    PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS (CTOS 2022)
    This Phase Ia/Ib study (NCT03964233) is assessing BI 907828, an MDM2–p53 antagonist, combined with immune checkpoint inhibitors in TP53 wild-type cancers. In Phase Ia (dose escalation), patients with advanced/metastatic solid tumors received escalating doses of BI 907828 guided by a Bayesian Logistic Regression Model (starting dose 10 mg orally) plus ezabenlimab 240 mg (anti-PD-1 antibody) and BI 754111 600 mg (anti-LAG-3 antibody) every 21 days (q3w). The doublet combination of BI 907828 plus ezabenlimab showed a manageable safety profile and early signs of anti-tumor activity. Eleven patients remain on treatment; recruitment is ongoing.
    P1 data • Preclinical • Combination therapy • Checkpoint inhibition
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    almost2years
    A Study to Determine How BI 907828 is Taken up in the Tumor and to Determine the Highest Dose of BI 907828 That Could be Tolerated in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma (clinicaltrials.gov)
    P1, N=35, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type • IDH wild-type
    |
    brigimadlin (BI 907828)
    almost2years
    A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor (clinicaltrials.gov)
    P1, N=16, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • rifampicin
    almost2years
    Brightline-1: A study to compare BI 907828 with doxorubicin in people with a type of cancer called dedifferentiated liposarcoma (clinicaltrialsregister.eu)
    P2/3, N=300, Ongoing, SCS Boehringer Ingelheim Comm. V`BOEHRINGER-INGELHEIM ITALIA S.P.A.`Boehringer Ingelheim Finland Ky`Boehringer Ingelheim España, S.A.`Boehringer Inge
    New P2/3 trial
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    doxorubicin hydrochloride • brigimadlin (BI 907828)
    almost2years
    This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1a/1b, N=204, Recruiting, Boehringer Ingelheim | N=114 --> 204
    Enrollment change
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    almost2years
    A Study to Determine How BI 907828 is Taken up in the Tumor and to Determine the Highest Dose of BI 907828 That Could be Tolerated in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Boehringer Ingelheim
    New P1 trial • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type • IDH wild-type
    |
    brigimadlin (BI 907828)
    2years
    A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Boehringer Ingelheim
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • rifampicin
    2years
    Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    doxorubicin hydrochloride • brigimadlin (BI 907828)
    2years
    This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1a/1b, N=114, Recruiting, Boehringer Ingelheim | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Mar 2023 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    2years
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1a/1b, N=144, Recruiting, Boehringer Ingelheim | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Oct 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    over2years
    Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma (clinicaltrials.gov)
    P2/3, N=300, Not yet recruiting, Boehringer Ingelheim
    New P2/3 trial
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    |
    doxorubicin hydrochloride • brigimadlin (BI 907828)